Published in Mental Health Business Week, January 27th, 2007
The company's wholly-owned subsidiary, Genaissance Pharmaceuticals, Inc., acquired the rights to develop and commercialize vilazodone from Merck KGaA of Darmstadt, Germany in September 2004. Under the terms of the license agreement, the company was required to make a milestone payment to Merck for the transfer of the vilazodone manufacturing technology in Clinical Data Common Stock equivalent in value to EUR...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Mental Health Business Week